Table 2 Roles of ferroptosis-associated TFs in neurological diseases.

AD

Inhibiting neuronal ferroptosis by activating Nrf2–HO-1 signaling pathway to exert neuroprotective effects

¹⁹⁷

Inhibiting ferroptosis-mediated neuroinflammation via Nrf2/GPX4 axis activation

¹⁰⁹

Inhibiting ferroptosis by promoting the nuclear translocation of Nrf2 and activating the Nrf2–FPN1 signaling pathway to against cognitive impairment

¹⁰¹

Inhibiting ferroptosis via the p53–SAT1–Alox15 signaling pathway to ameliorate cognitive dysfunction

⁴⁴

Inhibiting cardiac ferroptosis by suppressing Sp1–ACSL4 signaling pathway to exert cardioprotective effects

⁹⁹

Alleviating ferroptosis-induced damage by activating the PPAR-α–Nrf2–GPX4 signaling pathway to diminish cellular toxicity

¹⁹⁸

PD

Attenuating inflammation and OS via Nrf2–Keap1–SLC7A11 pathway

¹⁹⁹

Inhibiting ferroptosis via the Nrf2–HO-1 pathway to ameliorate the accumulation of α-synuclein

⁸⁷

Promoting ferroptosis via p53–SLC7A11–GPX4 pathway to attenuate cell senescence

²⁰⁰

Preventing ferroptosis via regulating iron metabolism to promote the clearance of α-synuclein

⁸⁵

Promoting ferroptosis via fostering synthesis of membrane phospholipids in α-syn-induced PD mice

⁸⁶

Inhibiting ferroptosis via the HIF-1α–SLC7A11 pathway to alleviate cell toxicity

⁹⁴

Promoting ferroptosis via Sp1–ACSL4 axis to attenuate neuron injury

⁹⁵

Epilepsy

Inhibiting ferroptosis via the PPAR-γ–Nrf2–Gpx4 pathway to alleviate seizures

²⁰¹

Promoting ferroptosis via increasing accumulation of Fe²⁺ to promote the development of epilepsy

²⁰²

Promoting ferroptosis via fostering lipid ROS production to alleviate neuronal injury

²⁰³

Promoting ferroptosis via the STAT3–SLC7A11 axis to improve susceptibility of epilepsy

¹⁹⁰

Promoting ferroptosis via stabilizing ATF3 mRNA expression by circSLC8A1

²⁰⁴

Stroke

Ameliorating ferroptosis via decreasing OS and LPO through the SATB1–SLC7A11–HO-1 signaling pathway

¹⁰⁴

Inhibiting ferroptosis to alleviate ischemic brain damage and inhibit proinflammatory cytokine production in microglia

²⁰⁵

Aggravating ferroptosis and OS to ameliorate cerebral ischemia–reperfusion injury

²⁰⁶

Inhibiting ferroptosis via driving transcription of GPX4 by a Sp1-mediated pathway to protect neurons

²⁰⁷

Promoting ferroptosis via STAT3–HIF-1α–PTRF axis to increase ROS production in cerebral I/R injury

¹⁰²

Inhibiting ferroptosis via the governance of iron homeostasis and LPO to mitigate ICH-induced neurological deficits

²⁰⁸

Inhibiting ferroptosis via Nrf2–HO-1–SLC7A11–GPX4 axis to have the neuroprotective effects

²⁰⁹

TBI

Inhibiting ferroptosis by reducing iron metabolism and inhibiting redox statuses to protect neurons

³⁶

Promoting ferroptosis via p53–SLC7A11 axis to inhibit neurological function and foster cerebral edema

¹⁹⁵

SCI

Promoting ferroptosis via aggravating cellular LPO to alleviate SCI

²¹⁰

Inhibiting ferroptosis via AMPK–Nrf2–HO-1 axis to attenuate neuronal death

²¹¹

Inhibiting microglial ferroptosis via PPAR-α–GPX4 axis to alleviate motor dysfunction

²¹²